North America is to Dominate the Bovine Serum Albumin Market Through 2019-2025

1
MarketsandMarkets Presents

•  
• North America is to Dominate the Bovine Serum
  Albumin Market through 2019- 2025

2
Introduction

• The bovine serum albumin market is estimated to
  account for a value of USD 255 million in 2019
  and is projected to grow at a CAGR of 3.0 from
  2019, to reach a value of USD 304 million by
  2025. The demand for bovine serum albumin has
  been growing in accordance with the rise in
  demand from the pharmaceutical industry. The
  other factors responsible for driving the global
  market are the changing consumer preferences for
  a protein-rich diet and high demand from the life
  sciences industry. 
• The North American and Asia Pacific countries are
  witnessing increasing demand for bovine serum
  albumin for the pharmaceutical and diagnostic
  industry. The growth of bovine serum albumin
  market in the North American region spurs from
  the high demand for red meat its products,
  alongside the dynamic changes in the meat
  processing industry in countries such as the US
  and Canada. The Asia Pacific region has a growing
  opportunity for the use of BSA in the
  pharmaceutical and technical industries, as the
  pharmaceutical industry is blooming in this
  region. China is the second-largest
  pharmaceutical market across the globe. To treat
  chronic diseases, the research development
  sector is witnessing high investments that will
  significantly drive the demand for innovative
  drugs.
• Read more _at_ https//www.marketsandmarkets.com/Pres
  sReleases/bovine-serum-albumin.asp

3
Key Players

• Thermo Fisher Scientific (US)
• Bio-Rad Laboratories, Inc (US)
• Merck KGAA (Germany)
• Itoham Yonekyu Holdings Inc (Japan)
• Proliant Biologicals (US)
• Kraeber Co Gmbh (Germany)
• Rockland Immunochemicals Inc (US)
• Rocky mountain biologicals (US)
• BelHealth investment partners, LLC (US)
• Bio-Techne Corporation (US)
• Prospec-Tany Technogene Ltd (Israel)
• LGC Group (UK)
• Promega Corporation (US)

4
(No Transcript)
5
 Market Dynamics

•  Drivers
• Inexpensive and Stable Nature of Bovine Serum
  Albumin as A Protein Standard
• Growth of the Livestock Industry and Consequent
  Demand Generation for Blood-Based Products
• Rise in Application in the Food Pharmaceutical
  Industries        
• Restraints
• Rise in Demand for Animal-Free Albumin Products
• Growth in Appeal to Replace Fetal Bovine Serum
  and Its Components in Cell Culture Applications

6

• Opportunities
• Scope for Use as A Dietary Protein for Fat
  Reduction
• Usage in the Biodegradable and Edible Food
  Packaging Industry
• Challenges
• Existence of Alternatives in the Diagnostic and
  Pharmaceutical Industries

7
Recent Developments in the Market

• In November 2017, Proliant Biologicals New
  Zealand facility launched a new reagent grade
  fatty acid-free BSA, which is derived from
  animals with origin in New Zealand.
• In February 2019, Proliant Biologicals launched
  its product line for Ultra-High Monomer BSA
  solution that is particularly designed to improve
  the performance of BSA in critical research.
• In 2018, Serion GmbH (Germany) expanded its
  SERION Diagnostics product division to increase
  its focus into in-vitro diagnostics.
• In February 2018, Merck KGAA invested USD 44.86
  million in a cell culture facility in South Korea
  to expand its life science segment in the Asia
  Pacific region this would help the company to
  cater to the markets in various geographies.
• In January 2018, Itoham Yonekyu Holdings Inc.
  (Japan) acquired Anzco Foods (New Zealand). This
  helped the company to expand itself in the bovine
  serum albumin markets of Australia and New
  Zealand, as it gained the control of Bovogen
  Biologicals, a subsidiary of Anzco Foods
  (NewZealand).
• In September 2018, BelHealth Investment Partners,
  LLC (US) acquired and invested USD 350 million in
  Gemini Bioproducts. Due to this investment, a
  wide range of bio-product manufacturing platform
  was created.
• In December 2018, LGC Group (UK) acquired
  SeraCare Life Sciences, Inc (US) to strengthen
  its presence in the molecular diagnostics market
  as well as reinforce its market position in
  clinical quality control tools.

8
Contact Us

• Mr. Shelly Singh
• MarketsandMarkets INC.
• 630 Dundee Road
• Suite 430
• Northbrook, IL 60062
• USA 1-888-600-6441
• sales_at_marketsandmarkets.com

9
About MarketsandMarkets

• MarketsandMarkets provides quantified B2B
  research on 30,000 high growth niche
  opportunities/threats which will impact 70 to
  80 of worldwide companies revenues. Currently
  servicing 7500 customers worldwide including 80
  of global Fortune 1000 companies as clients.
  Almost 75,000 top officers across eight
  industries worldwide approach MarketsandMarkets
  for their painpoints around revenues decisions.
• Our 850 fulltime analyst and SMEs at
  MarketsandMarkets are tracking global high
  growth markets following the "Growth Engagement
  Model GEM". The GEM aims at proactive
  collaboration with the clients to identify new
  opportunities, identify most important customers,
  write "Attack, avoid and defend" strategies,
  identify sources of incremental revenues for both
  the company and its competitors.
  MarketsandMarkets now coming up with 1,500
  MicroQuadrants (Positioning top players across
  leaders, emerging companies, innovators,
  strategic players) annually in high growth
  emerging segments. MarketsandMarkets is
  determined to benefit more than 10,000 companies
  this year for their revenue planning and help
  them take their innovations/disruptions early to
  the market by providing them research ahead of
  the curve.
• MarketsandMarketss flagship competitive
  intelligence and market research platform,
  "Knowledgestore" connects over 200,000 markets
  and entire value chains for deeper understanding
  of the unmet insights along with market sizing
  and forecasts of niche markets.